The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Onto better TRAILs for cancer treatment

(2016) D de Miguel et al.   CELL DEATH AND DIFFERENTIATION

Pancreatic cancer

(2016) Jorg Kleeff et al.   Nature Reviews Disease Primers

Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study

(2015) Roberto Petrioli et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and tolerability of TRAIL receptor agonists in cancer treatment

(2015) Simone Fulda   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer

(2015) Freya A. Goumas et al.   INTERNATIONAL JOURNAL OF CANCER

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL

(2015) Yoko Hari et al.   Oncotarget

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

(2015) Rachana Trivedi et al.   Frontiers in Oncology

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

(2014) Jonathan D. Graves et al.   CANCER CELL

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

(2014) M H Tuthill et al.   ONCOGENE

Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1

(2013) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family

(2013) K Azijli et al.   CELL DEATH AND DIFFERENTIATION

APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc  Receptors

(2013) C. Gieffers et al.   MOLECULAR CANCER THERAPEUTICS

Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth

(2012) Nicholas S. Wilson et al.   CANCER CELL

The Pancreas Cancer Microenvironment

(2012) C. Feig et al.   CLINICAL CANCER RESEARCH

A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death

(2012) Laura S. Dickens et al.   MOLECULAR CELL

Caspase-8 and Bid: Caught in the act between death receptors and mitochondria

(2011) Chahrazade Kantari et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells

(2010) Frederik J.H. Hoogwater et al.   GASTROENTEROLOGY

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

(2010) Johannes Lemke et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives

(2009) J.H. Stegehuis et al.   DRUG RESISTANCE UPDATES

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

(2008) M Todaro et al.   CELL DEATH AND DIFFERENTIATION

The p53 family and programmed cell death

(2008) E C Pietsch et al.   ONCOGENE